1. 55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study. (15th December 2019) Authors: Nigro, O; Cortellini, A; Giusti, R; Marchetti, P; De Galitiis, F; Di Pietro, F R; Bersanelli, M; Lazzarin, A; Galetta, D; Pizzutillo, P; Santini, D; Torniai, M; De Giglio, A; Russo, A; Silva, R R; Bolzacchini, E; Natoli, C; Rijavec, E; Vallini, I; Pinotti, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. C48Response rate by molecular subtypes and p53 expression in neoadjuvant therapy for breast cancer with TAC regimen: a single-centre experience. (6th November 2017) Authors: Marcon, I; Vallini, I; Bolzacchini, E; Ritorna, A; Giaquinto, A; Pinotti, G Journal: Annals of oncology Issue: Volume 28(2017)Supplement 6 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗